Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.82 |
| ▸ | MEN1 | O00255 | 2/20 | 0.82 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.70 |
| ▸ | POLB | P06746 | 1/20 | 0.70 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.70 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.64 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.59 |
| ▸ | BRD4 | O60885 | 1/20 | 0.59 |
| ▸ | NPC1 | O15118 | 1/20 | 0.59 |
| ▸ | GAA | P10253 | 1/20 | 0.57 |
| ▸ | MAPT | P10636 | 1/20 | 0.57 |
| ▸ | PKM | P14618 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27516231 | 0.95 | KMT2A (0.85) | KMT2AMEN1SMN1; SMN2POLBMAPK1 | |
| SCHEMBL10790461 | 0.90 | KMT2A (0.77) | KMT2AMEN1SMN1; SMN2POLBMAPK1 | |
| SCHEMBL30182819 | 0.88 | KMT2A (0.65) | KMT2AMEN1SMN1; SMN2POLBMAPK1 | |
| SCHEMBL7956522 | 0.86 | KMT2A (0.80) | KMT2AMEN1SMN1; SMN2POLBMAPK1 | |
| SCHEMBL27772554 | 0.86 | KMT2A (0.80) | KMT2AMEN1SMN1; SMN2POLBMAPK1 | |
| SCHEMBL31233748 | 0.86 | KMT2A (0.80) | KMT2AMEN1SMN1; SMN2POLBMAPK1 | |
| SCHEMBL20339052 | 0.85 | KMT2A (0.88) | KMT2AMEN1SMN1; SMN2POLBMAPK1 | |
| SCHEMBL20339060 | 0.85 | KMT2A (0.88) | KMT2AMEN1SMN1; SMN2POLBMAPK1 | |
| SCHEMBL2677556 | 0.85 | POLB (0.89) | KMT2AMEN1SMN1; SMN2POLBMAPK1 | |
| SCHEMBL7945854 | 0.85 | KMT2A (0.83) | KMT2AMEN1SMN1; SMN2POLBMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 58 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101087793-B | Novel substituted thiophenepyrimidinone derivatives as inhibitors of 17beta-hydroxysteroid dehydrogenase | SOLVAY PHARM BV | 2011-09-07 | — | — | CN | disclosed |
| US-20100305113-A1 | Substituted Imidazopyridazines as Lipid Kinase Inhibitors | CAPRARO HANS-GEORG | 2010-12-02 | — | — | US | disclosed |
| EP-1635839-B1 | BENZO[4,5]THIENO[2,3-D]PYRIMIDIN-4-ONES AND THEIR USE IN THERAPY | ABBOTT HEALTHCARE PRODUCTS BV (NL) | 2010-09-01 | — | — | EP | disclosed |
| EP-1828197-B1 | NOVEL SUBSTITUTED THIOPHENEPYRIMIDINONE DERIVATIVES AS INHIBITORS OF 17ß-HYDROXYSTEROID DEHYDROGENASE | SOLVAY PHARM GMBH (DE) | 2009-05-13 | — | — | EP | disclosed |
| US-7524853-B2 | Compounds and their use in therapy | SOLVAY PHARMACEUTICALS B.V. (NL) | 2009-04-28 | — | — | US | disclosed |
| US-7465739-B2 | Compounds and their use in therapy | SOLVAY PHARMACEUTICALS B.V. (NL) | 2008-12-16 | — | — | US | disclosed |
| CN-101087793-A | Novel substituted thiophenepyrimidinone derivatives as inhibitors of 17beta-hydroxysteroid dehydrogenase | SOLVAY PHARM BV (DE) | 2007-12-12 | — | — | CN | disclosed |
| US-20050176742-A1 | Novel compounds and their use in therapy | SOLVAY PHARMACEUTICALS B.V. (NL) | 2005-08-11 | — | — | US | disclosed |
| US-20050038053-A1 | Novel compounds and their use in therapy | SOLVAY PHARMACEUTICALS B.V. (NL) | 2005-02-17 | — | — | US | disclosed |
| US-4683330-A | ANTICOAGULANTS, ANTIULCER AGENTS | THE UPJOHN COMPANY (US) | 1987-07-28 | — | — | US | disclosed |
| US-4160095-A | PROSTAGLANDINS; ANTIINFLAMMATORY AGENTS | THE UPJOHN COMPANY (US) | 1979-07-03 | — | — | US | disclosed |
| US-4157441-A | PROSTAGLANDINS, ANTIINFLAMMATORY AGENTS | THE UPJOHN COMPANY (US) | 1979-06-05 | — | — | US | disclosed |
| US-4151351-A | PROSTAGLANDINS, ANTIINFLAMMATORY | THE UPJOHN COMPANY (US) | 1979-04-24 | — | — | US | disclosed |
| US-4131738-A | 6-Hydroxy-PGE1 compounds | THE UPJOHN COMPANY (US) | 1978-12-26 | — | — | US | disclosed |
| US-4128713-A | 6,7-Didehydro-PGI1 compounds | THE UPJOHN COMPANY (US) | 1978-12-05 | — | — | US | disclosed |
| US-4126744-A | PROSTACYCLIN, MUSCLE STIMULANTS, PLATELET AGGREGATION INHIBITORS | THE UPJOHN COMPANY (US) | 1978-11-21 | — | — | US | disclosed |
| US-4112224-A | PROSTAGLANDIN | THE UPJOHN COMPANY (US) | 1978-09-05 | — | — | US | disclosed |
| US-4109082-A | PROSTACYCLIN ANALOGS; SMOOTH MUSCLE STIMULATORS | THE UPJOHN COMPANY (US) | 1978-08-22 | — | — | US | disclosed |
| US-4100192-A | Inter-phenylene-PG amides | THE UPJOHN COMPANY (US) | 1978-07-11 | — | — | US | disclosed |
| US-4097489-A | PROSTAGLANDINS | THE UPJOHN COMPANY (US) | 1978-06-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100305113-A1 | Substituted Imidazopyridazines as Lipid Kinase Inhibitors | PI4KA, PIK3CA, PIK3CB | KMT2A 1287/4885MEN1 3912/4885SMN1; SMN2 4165/4885 |
| US-20050176742-A1 | Novel compounds and their use in therapy | HSD17B11, HSD17B2, HSD17B1 | KMT2A 2945/4885MEN1 2028/4885SMN1; SMN2 3338/4885 |
| US-20050038053-A1 | Novel compounds and their use in therapy | HSD17B11, HSD17B2, HSD17B1 | KMT2A 2945/4885MEN1 2028/4885SMN1; SMN2 3338/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.